Multiple Sclerosis and Fatigue Assessment

Sponsor
Asli Celik (Other)
Overall Status
Recruiting
CT.gov ID
NCT05820334
Collaborator
Gazi University (Other)
54
1
20
2.7

Study Details

Study Description

Brief Summary

Fatigue in patients with Multiple Sclerosis (MS) is a problem that is seen without physical exertion and affects the majority of patients. In studies on fatigue in the literature, it has been seen that subjective methods are frequently used by using evaluation scales based on patient statements, but objective evaluation methods are not yet sufficient. This study was planned to compare the measurement results by evaluating fatigue subjectively, objectively and cognitively in MS patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, autoimmune disease of the central nervous system. It is characterized by clinical symptoms arising from lesions in the brain, spinal cord or optic nerves. Although fatigue is one of the most common and most disabling problems of individuals with MS, it is not yet fully understood. This affects the treatment and disease process in MS. Despite studies to elucidate the pathogenic mechanisms of fatigue, available information is limited. Several factors contribute to the limited fatigue research, but the most important is that 'fatigue' is often not clearly defined or meaningful measures cannot be made in clinical/research settings. The first step in the evaluation of fatigue, which is a complex symptom, is to start with the identification and analysis of the factors that may cause fatigue, and to comprehensively question the factors that may be effective and the patient's history, and to evaluate the fatigue subjectively and objectively after the comprehensive patient history. The fatigue of patients diagnosed with MS will be evaluated subjectively, objectively and cognitively. Other information about the disease of the patients will be recorded. Subjective fatigue assessment methods, objective fatigue assessment methods and cognitive fatigue assessment methods will be applied.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    54 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Fatigue in Multiple Sclerosis Patients; Subjective, Objective and Cognitive Analysis
    Actual Study Start Date :
    Apr 1, 2023
    Anticipated Primary Completion Date :
    Dec 1, 2024
    Anticipated Study Completion Date :
    Dec 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Fatigue Severity [Baseline]

      In the Fatigue Severity Scale (FSS), participants are asked to rate their fatigue level between 1 and 7 in the 9 statements (including motivation, exercise, physical functioning, carrying out duties, and interfering with work, family, or social life) during the last week.The minimum score possible is 9 and the highest is 63. The higher score indicates more severe fatigue.

    2. Fatigue Impact [Baseline]

      The Fatigue Impact Scale (FIS) was first developed by Fisk to evaluate the symptoms of fatigue in disease states and the effects of fatigue on daily life. FIS considers the fatigue in the last month. It consists of 40 questions in total, investigating the effects of fatigue on cognitive (10 questions), physical (10 questions), and psychosocial (20 questions). Since each question is scored between 0 (no problem) and 4 (maximum problem), the total score of the scale is 160, and an increase in the score means that the effect of fatigue increases. Cognitive function, memory, thinking and regulation; physical function motivation, endurance and effort; psychosocial function evaluates the effect of fatigue on emotions, coping and workload based on self-report.

    3. Fatigue Assessment [Baseline]

      "Checklist Individual Strength" (CIS) Scale: It was developed by Beurskens and adapted into Turkish by Ergin to measure the general fatigue levels of individuals. It is a valid and reliable fatigue assessment scale in patients with MS. According to this scale, fatigue; subjective perception of fatigue is evaluated in four aspects as decrease in concentration, decrease in motivation and decrease in physical activity. The questionnaire consists of 20 statements measuring the fatigue in the last 2 weeks and a 7-point scale is used for the answers. The lowest score that can be obtained from the scale is 20, and the highest score is 140.

    4. Cognitive Fatigue Assessment [Baseline]

      The Brief International Cognitive Assessment for MS (BICAMS) initiative was undertaken to recommend a brief, cognitive assessment for MS that is optimized for small centers. BICAMS was particularly focused on international use, to facilitate comparison across settings. An expert committee of twelve neurologists and neuropsychologists representing the main cultural groups that have so far contributed extensive data about cognitive dysfunction in MS was convened. The opinions generated from the meeting are published elsewhere. Consensus was also achieved on optimal measures for learning and memory in MS patients, time permitting: the initial learning trials of the second edition of the California Verbal Learning Test (CVLT2) and the revised Brief Visuospatial Memory Test (BVMTR).

    5. Lower extremity functions [Baseline]

      The 25-Step Walking Test is a test that measures lower extremity functions. It has been developed for the purpose of recording the patient with this test at each examination. The patient is asked to walk in a predetermined interval. The average of both times is taken by noting the number of seconds spent on the way out and on the way back.

    6. Upper extremity functions [Baseline]

      Upper extremity function was evaluated with the 9-Hole Peg Test (9-HPT). It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. A stopwatch was used for the measurements and the scores were recorded in seconds (s).

    7. Hand grip-fatigue assessment [Baseline]

      In order to evaluate the fatigue that may occur due to time, the grip muscle strength that individuals can sustain for a certain period of time will be evaluated. A 'K-Force Grip grip dynamometer' will be used for the measurement. The values and fatigue level will be recorded by making three attempts for both hands in the determined position. The test will be administered for 30 seconds. A 1-minute rest will be given between measurements. The average value for fatigue and grip strength will be calculated.

    8. Muscle strength-fatigue assessment [Baseline]

      Fatigue is automatically calculated and reported by the K-Force device. The device software fatigue value is calculated based on the changes in performance during muscle contraction. In the evaluation of muscle strength, the 'K-Force Muscle Controller' will be evaluated using a muscle dynamometer. For the lower extremity, hip flexion, hip abduction, and knee extension will be evaluated bilaterally. Shoulder flexion, shoulder abduction and elbow flexion muscle strength will be evaluated for the upper extremity. In the lower and upper extremities, the measurement will be repeated 3 times for both sides and the average value will be calculated and recorded. A 1-minute rest will be given between measurements. The fatigue value determined for each measurement will also be recorded. Test positions applied during manual muscle testing will be applied to provide standardization for assessment.

    9. Balance-fatigue assessment [Baseline]

      In order to evaluate the fatigue that may occur due to performance, the balance of individuals and the resulting fatigue will be evaluated using the Visual Analog Scale-Fatigue (VAS-F) before and after the balance changes calculated from the device during the balance tests. It will be evaluated using the 'Force Plates' device in the evaluation of balance. Foot sole pressure distributions, ground reaction forces, static and dynamic balance evaluations, symmetry will be evaluated. For static balance; balance on one leg, balance on both legs with eyes open and eyes closed will be evaluated. dynamic balance; will be evaluated by the squat assessment. Measurements will be repeated 3 times and the average value will be calculated and recorded. A 1-minute rest will be given between measurements. The higher scores mean a worse in assessment.

    Secondary Outcome Measures

    1. Extended Disability Status Scale (EDSS) [Baseline]

      Expanded Disability Status Scale (EDSS) is the most commonly used scale to monitor disease stage and assess disability in multiple sclerosis patients. Eight functional systems (FS) are evaluated with EDSS (Visual functions, brain stem functions, pyramidal functions, cerebellar functions, sensory functions, bladder and bowel functions, cerebral functions and other). In addition, gait is also evaluated and a score between 0 (normal neurological status) and 10 (death due to MS) is determined by considering functional system scores and the level of independence of the patient in ambulation.

    2. Standardized Mini Mental Test [Baseline]

      There are 19 items in this test, which consists of 5 main parts: orientation, recording memory, attention and calculation, recall and language. The total score of the test is evaluated out of 30 and 24 points are accepted as the threshold value for the diagnosis of mild dementia. The higher the score, the higher the cognition of individuals.

    3. Subjective fatigue assessment [Baseline]

      A visual analog scale will be used.Their values range from 0-10. The higher scores mean a worse in assessment.

    Other Outcome Measures

    1. Interview form [Baseline]

      With a questionnaire prepared by the researchers and applied by face-to-face interview method; age (year), height (cm), body weight (kg), body mass index (BMI- kg/m2), year of diagnosis, frequency of attacks, date of last attack, marital status (married/single), education level Information such as (literate, primary school, secondary school, high school, associate degree, undergraduate, graduate), dominant extremity (right, left), CV and family history, use of assistive devices, smoking and alcohol habits, drugs used, and surgeries will be recorded.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Being between the ages of 18-65,

    • Having a definite diagnosis of Relapsing Remitting MS by a neurologist,

    • Expanded Disability Status Scale (EDSS) score between 1-5.5,

    • To be stable in medical treatment,

    • Being able to stand independently for at least 60 seconds without any assistive device,

    • It is to be above 24 points according to the Mini-Mental State Examination (MMSE) evaluation.

    Exclusion Criteria:
    • Being diagnosed with MS for less than 1 year,

    • Having had an MS attack in the last 3 months,

    • Being illiterate or unable to communicate in Turkish,

    • Having an active infection,

    • Being pregnant,

    • Having an orthopedic problem or having a surgery that may affect the lower extremity,

    • Having an additional neurological or circulatory disease that may cause balance disorder, a problem affecting the vision or vestibular tract, or a diagnosis of orthopedic surgery, rheumatological disease,

    • To be included in the physiotherapy and rehabilitation program in the last 3 months.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Gazi University Ankara Turkey 06490

    Sponsors and Collaborators

    • Asli Celik
    • Gazi University

    Investigators

    • Principal Investigator: İlke KESER, Prof. Dr., Gazi University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Asli Celik, Lecturer, MSc., PT., Nigde Omer Halisdemir University
    ClinicalTrials.gov Identifier:
    NCT05820334
    Other Study ID Numbers:
    • 2023-157
    First Posted:
    Apr 19, 2023
    Last Update Posted:
    Apr 21, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Asli Celik, Lecturer, MSc., PT., Nigde Omer Halisdemir University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 21, 2023